Medical Devices

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.

NAMSA appoints commercial leader Scott Day as VP, signaling a strategic push to expand its end-to-end clinical and consulting services amid industry growth.

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

A new gene therapy that reprograms cancer cells into immune activators shows major promise, blending personalized treatment with off-the-shelf convenience.

In a crowded market, Zomee's focus on human support, not just tech, earned it a top spot on USA TODAY's first-ever list of most trusted parent brands.

A landmark real-world study from England shows maternal RSV vaccination slashes infant hospitalizations, validating a powerful new shield for newborns.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

New data on ATX-295 reveals a potent attack on unstable tumors, guided by an AI biomarker that could change how we select patients for treatment.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

A new partnership between Wilcrest Pharma and healthcare giant Premier, Inc. aims to streamline hazardous drug compounding for thousands of U.S. hospitals.

New clinical consensus on ammonia and scrutiny of a standard antibiotic are creating a perfect storm for Yaqrit's promising new liver disease treatments.

With global regulatory approvals secured, Gilead extends its tender offer for Arcellx, moving closer to acquiring a potential best-in-class CAR T therapy.

With $16M in new funding and landmark trial results, ScreenPoint Medical is poised to redefine breast cancer screening with its powerful AI technology.

Preliminary Q1 data from Auna shows rising demand for specialized care in Peru, Colombia, and Mexico, offering investors a transparent new look.

BioPhotas launches the first FDA-cleared LED mask for acne, wrinkles, and hair loss, aiming to redefine at-home beauty tech with its new MYSTIQUE device.

Early Phase 2 data shows invikafusp alfa plus TRODELVY® yields complete responses in heavily pretreated breast cancer, offering a potential new lifeline.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.